Key facts
- Maxwell Biosciences’s last known valuation is $50.9M (Oct 2023).
- It has raised $35.5M across 1 recorded rounds; the latest was Early Stage VC ($10.9M) in Oct 2021.
- Notable investors include U.S. Department of Energy, Capital Factory, National Institutes of Health, Keiretsu Forum, Endless Frontier Labs — 30 tracked in total.
- Maxwell Biosciences has filed 2 Form Ds with the SEC since 2022, most recently Jul 2023 ( sold).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 30 names
- ·Watchlist + deal alerts for Maxwell Biosciences
Funding rounds
1 roundsAbout Maxwell Biosciences
Operator of a drug platform company intended to create biomimetic therapeutics and synthetic compounds that mimic and improve upon biomolecules. The company's platform effectively destroys viruses, bacteria, fungi, and some cancers, while avoiding healthy cells in human tissues and animal studies, where compounds imitate key immune system components, enabling healthcare professionals to treat formerly untreatable conditions.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2016
- Employees
- 23
- Website
- maxwellbiosciences.com/
- Ownership
- Privately Held (backing)
Maxwell Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Maxwell Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Maxwell Biosciences in its N-PORT filings yet. We sweep new filings monthly.